Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma

Immunotherapy

Volumn 8, Issue 6, 2016, Pages 677-679

  Spain, Lavinia ^a   Larkin, James ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ipilimumab; melanoma; nivolumab; pembrolizumab; survival; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 ANTIBODY; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

BRAF GENE; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; GENE MUTATION; HUMAN; MEDICAL DECISION MAKING; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; ADVERSE DRUG REACTION; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84971233985     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.16.6     Document Type: Review

References (16)

1. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
2. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
3. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. doi:10.1056/NEJMoa1504030 (2015) (Epub ahead of print).
4. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. doi:10.1056/NEJMoa1503093 (2015) (Epub ahead of print).
5. Mcarthur GA, Chapman PB, Robert C et al. Safety and effcacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label st udy. Lancet Oncol. 15(3), 323-332 (2014).
6. Weber J, Antonia S, Topalian SL American Society Clinical Oncology (ASCO) et al. Safety profle of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. Presented at:. J. Clin. Oncol. 33(Suppl.) (Abstract 9018). Chicago, IL, USA 3-7 June 2015.
7. Horvat TZ, Adel NG, Dang TO et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33 (28), 3193-3198 (2015).
8. Yousaf N, Davidson M, Goode E et al. The cost of ipilimumab toxicity: a single-centre analysis. Mel. Res. 25(3), 259-264 (2015).
9. Diem S, Kasenda B, Martin-Liberal J et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur. J. Cancer 51(18), 2785-2791 (2015).
10. Kelderman S, Heemskerk B, Van Tinteren H et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunoth. CII 63(5), 449-458 (2014).
11. Diem S, Kasenda B, Spain L et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer doi:10.1038/bjc.2015.467 (2016) (Epub ahead of print).
12. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, Phase 3 trial. Lancet Oncol. 16(5), 522-530 (2015).
13. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J. Clin. Oncol. 32 (19), e69-71 (2014).
14. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and effcacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J. Immuno. Cancer 322 (2015).
15. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J. Immuno. Cancer 2(1), 35 (2014).
16. Johnson DB, Khushalani NI, Puzanov I et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. J. Clin. Oncol. 33(Suppl.) (Abstract 9019), (2015).